Pascal Soriot was knighted for his leadership at AstraZeneca, transforming it into the UK's most valuable company. He is contemplating moving AstraZeneca's stock market listing to the US, causing alarm in Britain's scientific community. This potential relocation threatens the UK industrial strategy and could result in losing a major corporate player. Share prices fluctuated following these discussions. Soriot has voiced dissatisfaction with UK regulation, citing delays in NHS approval for critical drugs and the company's abandoned investment in a vaccine hub due to unmet support expectations.
Pascal Soriot received a knighthood for turning around AstraZeneca and leading the global Covid pandemic response, growing the company into Britain's most valuable firm.
Soriot has considered moving AstraZeneca's stock market listing and corporate base to the US, raising concerns in Britain's scientific community and threatening UK industrial strategy.
The share price of AstraZeneca rose by 2.8% following news of potential relocation but dipped slightly afterward, giving the company a valuation of nearly £161 billion.
Soriot expressed frustration over the UK regulatory environment, as AstraZeneca's drugs face approval delays and investments falter due to lack of governmental support.
Collection
[
|
...
]